LDLR and cardiovascular disorder: Since the first observations confirming the association of PCSK9 with enhanced hepatic LDLR degradation and elevated plasma LDLc concentrations, a number of additional actions of PCSK9 have been identified that are central to the development of cardiovascular diseases.